Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma

Andy Chen, R. S. Negrin, A. McMillan, J. A. Shizuru, L. J. Johnston, R. Lowsky, D. B. Miklos, S. Arai, W. K. Weng, G. G. Laport, K. Stockerl-Goldstein

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Single autologous hematopoietic cell transplant (AHCT) with high-dose melphalan prolongs survival in patients with multiple myeloma but is not curative. We conducted a study of intensive single AHCT using tandem chemo-mobilization with CY and etoposide followed by high-dose conditioning with melphalan 200 mg/m 2 plus carmustine 15 mg/kg. One hundred and eighteen patients in first consolidation (CON1) and 58 patients in relapse (REL) were transplanted using this intensified approach. Disease response improved from 32% very good PR (VGPR)+CR pre-mobilization to 76% VGPR+CR post transplant in CON1. With a median follow-up of 4.7 years, the median EFS was 2.8 years, and the median OS was 5.1 years in CON1. OS from time of transplant was significantly shorter for REL (3.4 years) compared with CON1 (5.1 years; P=0.02). However, OS from time of diagnosis was similar in REL (6.1 years) and CON1 (6.0 years; P=0.80). The 100-day non-relapse mortality in the CON1 and REL groups was 0% and 7%, respectively. In summary, intensified single AHCT with tandem chemo-mobilization and augmented high-dose therapy is feasible in multiple myeloma and leads to high-quality response rates.

Original languageEnglish (US)
Pages (from-to)516-521
Number of pages6
JournalBone Marrow Transplantation
Volume47
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Carmustine
Melphalan
Cell Transplantation
Multiple Myeloma
Transplants
Recurrence
Etoposide
Survival
Mortality

Keywords

  • autologous
  • myeloma
  • transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. / Chen, Andy; Negrin, R. S.; McMillan, A.; Shizuru, J. A.; Johnston, L. J.; Lowsky, R.; Miklos, D. B.; Arai, S.; Weng, W. K.; Laport, G. G.; Stockerl-Goldstein, K.

In: Bone Marrow Transplantation, Vol. 47, No. 4, 04.2012, p. 516-521.

Research output: Contribution to journalArticle

Chen, A, Negrin, RS, McMillan, A, Shizuru, JA, Johnston, LJ, Lowsky, R, Miklos, DB, Arai, S, Weng, WK, Laport, GG & Stockerl-Goldstein, K 2012, 'Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma', Bone Marrow Transplantation, vol. 47, no. 4, pp. 516-521. https://doi.org/10.1038/bmt.2011.106
Chen, Andy ; Negrin, R. S. ; McMillan, A. ; Shizuru, J. A. ; Johnston, L. J. ; Lowsky, R. ; Miklos, D. B. ; Arai, S. ; Weng, W. K. ; Laport, G. G. ; Stockerl-Goldstein, K. / Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 4. pp. 516-521.
@article{5c67aa1b7aeb4e73a8295ba3a46cda6b,
title = "Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma",
abstract = "Single autologous hematopoietic cell transplant (AHCT) with high-dose melphalan prolongs survival in patients with multiple myeloma but is not curative. We conducted a study of intensive single AHCT using tandem chemo-mobilization with CY and etoposide followed by high-dose conditioning with melphalan 200 mg/m 2 plus carmustine 15 mg/kg. One hundred and eighteen patients in first consolidation (CON1) and 58 patients in relapse (REL) were transplanted using this intensified approach. Disease response improved from 32{\%} very good PR (VGPR)+CR pre-mobilization to 76{\%} VGPR+CR post transplant in CON1. With a median follow-up of 4.7 years, the median EFS was 2.8 years, and the median OS was 5.1 years in CON1. OS from time of transplant was significantly shorter for REL (3.4 years) compared with CON1 (5.1 years; P=0.02). However, OS from time of diagnosis was similar in REL (6.1 years) and CON1 (6.0 years; P=0.80). The 100-day non-relapse mortality in the CON1 and REL groups was 0{\%} and 7{\%}, respectively. In summary, intensified single AHCT with tandem chemo-mobilization and augmented high-dose therapy is feasible in multiple myeloma and leads to high-quality response rates.",
keywords = "autologous, myeloma, transplant",
author = "Andy Chen and Negrin, {R. S.} and A. McMillan and Shizuru, {J. A.} and Johnston, {L. J.} and R. Lowsky and Miklos, {D. B.} and S. Arai and Weng, {W. K.} and Laport, {G. G.} and K. Stockerl-Goldstein",
year = "2012",
month = "4",
doi = "10.1038/bmt.2011.106",
language = "English (US)",
volume = "47",
pages = "516--521",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma

AU - Chen, Andy

AU - Negrin, R. S.

AU - McMillan, A.

AU - Shizuru, J. A.

AU - Johnston, L. J.

AU - Lowsky, R.

AU - Miklos, D. B.

AU - Arai, S.

AU - Weng, W. K.

AU - Laport, G. G.

AU - Stockerl-Goldstein, K.

PY - 2012/4

Y1 - 2012/4

N2 - Single autologous hematopoietic cell transplant (AHCT) with high-dose melphalan prolongs survival in patients with multiple myeloma but is not curative. We conducted a study of intensive single AHCT using tandem chemo-mobilization with CY and etoposide followed by high-dose conditioning with melphalan 200 mg/m 2 plus carmustine 15 mg/kg. One hundred and eighteen patients in first consolidation (CON1) and 58 patients in relapse (REL) were transplanted using this intensified approach. Disease response improved from 32% very good PR (VGPR)+CR pre-mobilization to 76% VGPR+CR post transplant in CON1. With a median follow-up of 4.7 years, the median EFS was 2.8 years, and the median OS was 5.1 years in CON1. OS from time of transplant was significantly shorter for REL (3.4 years) compared with CON1 (5.1 years; P=0.02). However, OS from time of diagnosis was similar in REL (6.1 years) and CON1 (6.0 years; P=0.80). The 100-day non-relapse mortality in the CON1 and REL groups was 0% and 7%, respectively. In summary, intensified single AHCT with tandem chemo-mobilization and augmented high-dose therapy is feasible in multiple myeloma and leads to high-quality response rates.

AB - Single autologous hematopoietic cell transplant (AHCT) with high-dose melphalan prolongs survival in patients with multiple myeloma but is not curative. We conducted a study of intensive single AHCT using tandem chemo-mobilization with CY and etoposide followed by high-dose conditioning with melphalan 200 mg/m 2 plus carmustine 15 mg/kg. One hundred and eighteen patients in first consolidation (CON1) and 58 patients in relapse (REL) were transplanted using this intensified approach. Disease response improved from 32% very good PR (VGPR)+CR pre-mobilization to 76% VGPR+CR post transplant in CON1. With a median follow-up of 4.7 years, the median EFS was 2.8 years, and the median OS was 5.1 years in CON1. OS from time of transplant was significantly shorter for REL (3.4 years) compared with CON1 (5.1 years; P=0.02). However, OS from time of diagnosis was similar in REL (6.1 years) and CON1 (6.0 years; P=0.80). The 100-day non-relapse mortality in the CON1 and REL groups was 0% and 7%, respectively. In summary, intensified single AHCT with tandem chemo-mobilization and augmented high-dose therapy is feasible in multiple myeloma and leads to high-quality response rates.

KW - autologous

KW - myeloma

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=84859456477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859456477&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.106

DO - 10.1038/bmt.2011.106

M3 - Article

VL - 47

SP - 516

EP - 521

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -